Skip to main content
BIO-FD&C CO.,LTD. logo

BIO-FD&C CO.,LTD. — Investor Relations & Filings

Ticker · 251120 ISIN · KR7251120002 KO Manufacturing
Open in API
Filings indexed 95 across all filing types
Latest filing 2022-03-23 Audit Report / Informat…
Country KR South Korea
Listing KO 251120

About BIO-FD&C CO.,LTD.

https://www.biofdnc.com/?lang=en

BIO-FD&C CO.,LTD. is a biotechnology company specializing in research and development based on a proprietary, sustainable plant cell platform technology. The company develops and commercializes high-value active ingredients for the cosmetics, pharmaceutical, and food industries. Its product portfolio includes plant cell-derived materials, bioactive recombinant proteins, growth factors, and peptides, with a significant focus on anti-aging ingredients for cosmeceuticals. Leveraging advanced techniques such as bioreactor cultivation, radiofrequency-enhanced production of bioactive compounds (SMART-RC2), and plant cell cryopreservation, the company is also exploring the development of plant cell-based therapeutics, including antibodies and vaccines.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/proper), key financial data, and auditor information for the fiscal year. While it contains financial data, it is a standard regulatory disclosure form announcing the receipt and submission of the audit report rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2021
2022-03-23 Korean
사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'BioFD&C' (주식회사 바이오에프디엔씨). It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements for the fiscal years 2020 and 2021. While it contains financial data, it is specifically structured as an audit report issued by an accounting firm (Samil PwC), which falls under the 'Audit Report / Information' category. FY 2021
2022-03-23 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (BioFD&C) regarding a significant change in revenue or profit structure (30% or more). This type of disclosure is a standard regulatory requirement in the Korean stock market (DART system) for reporting material financial changes. Since it provides specific financial highlights and performance metrics rather than just announcing the availability of a report, it falls under the Earnings Release (ER) category as it serves as an initial announcement of financial results. FY 2021
2022-03-14 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by BioFD&C. It outlines the date, location, and agenda items (such as financial statement approval, board remuneration, and articles of incorporation changes) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation/notice of meeting material provided to shareholders to inform them of the meeting and the items to be voted upon.
2022-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for BioFD&C. It contains the meeting agenda, date, location, and detailed management information including board activities, financial statements, and business overview. This type of document is standard for proxy solicitation and shareholder information provided ahead of an AGM, which falls under the Proxy Solicitation & Information Statement category.
2022-03-14 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a regulatory filing from BioFD&C regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date where many companies hold their AGMs). It explains the rationale for choosing March 31, 2022, and acknowledges the KOSDAQ Association's guidelines on AGM dispersion. Since this is a regulatory notification regarding meeting logistics rather than the meeting materials themselves or the results, it falls under the general regulatory filing category.
2022-03-14 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.